Skip to main content

Advertisement

SpringerLink
Log in

Will new human papillomavirus diagnostics improve cervical cancer control efforts?

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

With the causal link between specific types of human papillomavirus (HPV) and cervical cancer firmly established, efforts have turned to assessing the relative merits of offering HPV testing in screening, triage, and posttreatment management. Many unanswered questions remain, but a growing body of evidence supports a role for HPV testing in cervical cancer prevention programs. Already, clinical centers that serve thousands of women in Europe and the United States have incorporated HPV DNA tests in triage algorithms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Saseni P, Adams J: Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ 1999, 318:1244–1245.

    Google Scholar 

  2. Forsmo S, Buhaug H, Skjeldestad FE, Haugen OA: Treatment of pre-invasive conditions during opportunistic screening and its effectiveness on cervical cancer incidence in one Norwegian county. Int J Caner 1997, 71:4–8.

    Article  CAS  Google Scholar 

  3. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. In Human Papillomaviruses, vol. 64. Lyon: International Agency for Research on Cancer; 1995.

  4. Sasieni PD, Cuzick J, Lynch-Farmery E: Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 1996, 73:1001–1005.

    PubMed  CAS  Google Scholar 

  5. Gay JD, Donaldson LD, Goellner JR: False negative results in cervical cytology studies. Acta Cytol 1985, 29:1043–1046.

    PubMed  CAS  Google Scholar 

  6. Miller AB. Screening options: summary of the international review conferences held in 1999 [abstract]. In Proceedings of the 18th International Papillomavirus Conference. Barcelona, Spain: July 24–28, 2000.

  7. Claeys P, Gonzalez C, Gonzalez M, Temmerman M: Poor quality: main issue in cervical cancer screening in Nicaragua [abstract]. In Proceedings of the 18th International Papillomavirus Conference. Barcelona, Spain: July 24–28, 2000.

  8. Kuhn L, Denny L, Pollack A, et al.: Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000, 92:818–825. An examination of HPV testing in a setting with no established cervical cancer screening program.

    Article  PubMed  CAS  Google Scholar 

  9. Mitchell MF, Schottenfeld D, Tortolero-Luna G, et al.: Colposcopy for the diagnosis of squamous intraepithelial lesions of the cervix: a meta-analysis. Obstet Gynecol 1998, 91:626–631.

    Article  PubMed  CAS  Google Scholar 

  10. Mitchell MF, Cantor SB, Ramanujam N, et al.: Fluorescence spectroscopy for diagnosis of intraepithelial lesions of the cervix. Obstet Gynecol 1999, 93:462–470.

    Article  PubMed  CAS  Google Scholar 

  11. Mitchell MF, Cantor SB, Brookner C, et al.: Screening for squamous intraepithelial lesions with florescence spectroscopy. Obstet Gynecol 1999, 94:889–896.

    Article  PubMed  CAS  Google Scholar 

  12. Cuzick J, Saseni P, Davies P, et al.: A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess, 1999, 3:I-iv. A comprehensive review of HPV testing that addresses numerous issues surrounding its adoption.

    PubMed  CAS  Google Scholar 

  13. Lorincz AT: Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin North Am 1996: 23:707–730.

    Article  PubMed  CAS  Google Scholar 

  14. Cuzick J. Human papillomavirus testing for primary cervical cancer screening. JAMA 2000, 283:108–109.

    Article  PubMed  CAS  Google Scholar 

  15. Ylitalo N, Sorensen P, Josefsson AM, et al.: Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000, 355:2194–2198.

    Article  PubMed  CAS  Google Scholar 

  16. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al.:Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354:20–25.

    Article  PubMed  CAS  Google Scholar 

  17. Ho GY, Burk RD, Klein S, et al.: Persistent genital human papilloma-virus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87:1365–1371.

    Article  PubMed  CAS  Google Scholar 

  18. Swan DC, Tucker RA, Tortolero-Luna G, et al.: Human papillomavirus (HPV) DNA copy number is dependent on the grade of cervical disease and HPV type. J Clin Microbiol 1999, 37:1030–1034.

    PubMed  CAS  Google Scholar 

  19. Clavel C, Masure M, Levert M, et al.: Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions. Diagn Mol Pathol 2000, 9:145–150.

    Article  PubMed  CAS  Google Scholar 

  20. Forslund O, Lindqvist P, Haadem K, et al.: HPV 16 DNA and mRNA in cervical brush samples quantified by PCR and microwell hybridization. J Virol Method 1997, 69:209–222.

    Article  CAS  Google Scholar 

  21. Luff RD: The Bethesda system for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda Workshop. Hum Pathol 1992, 23:719–721.

    Article  PubMed  CAS  Google Scholar 

  22. Davey DD, Naryshkin S, Nielsen ML, Kline TS: Atypical squamous cells of undetermined significance: interlaboratory comparison and quality assurance monitors. Diagn Cytopathol 1994, 11:390–396.

    Article  PubMed  CAS  Google Scholar 

  23. Kinney WK, Manos MM, Hurley LB, et al.: Where’s the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolau diagnoses. Obstet Gynecol 1998, 91:973–976.

    Article  PubMed  CAS  Google Scholar 

  24. Sherman ME, Schiffman MH, Lorincz AT, et al.: Toward objective quality assurance in cervical cytopathology. Correlation of cytopathological diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994, 102:182–187.

    PubMed  CAS  Google Scholar 

  25. The ALTS Group: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000, 92:397–402. Definitive findings from a randomized control trial that examines the use of HPV testing for triage of LSIL smears.

    Article  Google Scholar 

  26. Falls RK: Spontaneous resolution rate of grade 1 cervical intraepithelial neoplasia in a private practice population. Am J Obstet Gynecol 1999 181:278–282.

    Article  PubMed  CAS  Google Scholar 

  27. Cox JT, Lorincz AT, Schiffman MH, et al.: Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995 172:946–954.

    Article  PubMed  CAS  Google Scholar 

  28. Ferris DG, Wright TC, Litaker MS, et al.: Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear; HPV DNA testing or colposcopy? J Fam Pract 1998, 46:125–134.

    PubMed  CAS  Google Scholar 

  29. Kaufman RH, Adam E, Icenogle J, et al.: Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity and cost-effectiveness. Am J Obstet Gyn 1997, 177:930–936.

    Article  CAS  Google Scholar 

  30. Lin CT, Tseng CJ, Lai CH, et al.: High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > 50 years of age. J Reprod Med 2000, 45:345–350.

    PubMed  CAS  Google Scholar 

  31. Bergeron C, Jeannel D, Poveda JD, et al.: Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000, 95:821–827.

    Article  PubMed  CAS  Google Scholar 

  32. MM Manos, Kinney WK, Hurley LB, et al.: Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolau results. JAMA 1999, 281:1605–1610. A large health maintenance organization-based study examining triage options that include HPV testing for women who have ASCUS Pap smears.

    Article  PubMed  CAS  Google Scholar 

  33. Solomon D, Schiffman M, Tarone B, for the ALTS Group: Comparison of three management strategies for patients with atypical squamous cells of undetermined significance (ASCUS): baseline results from a randomized trial. J Natl Cancer Inst 2001, 93:in press.

  34. Clavel C, Masure M, Bory J-P, et al.: Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999, 80:1306–1311.

    Article  PubMed  CAS  Google Scholar 

  35. Ratnam S, Franco E, Ferenczy A: Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prevent 2000, 9:945–951.

    CAS  Google Scholar 

  36. Cuzick J, Szarewski A, Terry G, et al.: Human papillomavirus testing in primary cervical screening. Lancet 1995, 345:1533–1536.

    Article  PubMed  CAS  Google Scholar 

  37. Cuzick J, Beverley E, Ho L, et al.: HPV testing in primary screening of older women. Br J Cancer 1999, 81:554–558.

    Article  PubMed  CAS  Google Scholar 

  38. Ho GYF, Bierman R, Beardsley L, et al.: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1999, 338:423–428.

    Article  Google Scholar 

  39. ACOG Committee Opinion: Recommendations on frequency of Pap test screening. Int J Gynecol Obstet 1995, 49:210–211.

    Article  Google Scholar 

  40. Koutsky LA, Holmes KK, Critchlow CW, et al.: A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992, 327:1272–1278.

    Article  PubMed  CAS  Google Scholar 

  41. Krone MR, Koutsky LA, Kiviat NB: Epidemiology of cervical neoplasia. In Intraepithelial Neoplasia of the Female Lower Genital Tract. Edited by Jordan J, Richart R, Luesley D. Edinburgh: Churchill Livingstone; 1995:49–60.

    Google Scholar 

  42. McCrory DC, Mather DB, Bastian L, et al.: Evaluation of cervical cytology. Evidence report/technology assessment no. 5 (prepared by Duke University under contract no. 290-97-0014). AHCPR publication no. 99-E010. Rockville, MD: Agency for Health Care Policy and Research; 1999.

  43. Elfgren K, Bistoletti P, Dillner L, et al.: Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 1996, 174:937–942.

    Article  PubMed  CAS  Google Scholar 

  44. Bollen LJM, Tjong-a-Hung SP, van der Velden J, et al.: Human papillomavirus DNA after treatment of cervical dysplasia. Cancer 1996, 77:2538–2543.

    Article  PubMed  CAS  Google Scholar 

  45. Chua KL, Hjerpe A: Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 1997, 66:108–113.

    Article  PubMed  CAS  Google Scholar 

  46. Harper DM, Hildesheim A, Cobb JL, et al.: Collection devices for human papillomaviruses. J Fam Pract 1999, 48:531–535.

    PubMed  CAS  Google Scholar 

  47. Harper DM, Noll WW, Belloni D, Cole B: Comparison of self-directed swabs and tampons to physician-directed sampling for human papillomavirus testing by PCR: biological concordance and women’s preferences [abstract]. In Proceedings of the 18th International Papillomavirus Conference. Barcelona, Spain: July 24–28, 2000.

  48. Hillemanns P, Kimmig R, Huttemann U, et al.: Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet 1999, 354:1970.

    Article  PubMed  CAS  Google Scholar 

  49. WrightTC, Denney L, Kuhn L, et al.: HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000, 283:81–86. An examination of HPV self testing compared with clinician testing in a low-resource setting.

    Article  Google Scholar 

  50. Salmeron J, Lazcano EC, Hernandez M, et al.: Evaluation of a high-risk HPV assay on self-sampled vaginal specimens as an alternative for cervical cancer screening in Morelos, Mexico [abstract]. In Proceedings of the 18th International Papillomavirus Conference. Barcelona, Spain: July 24–28, 2000.

  51. Vernon SD, Hart CE, Reeves WC, Icenogle JP: The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 1993, 27:133–145.

    Article  PubMed  CAS  Google Scholar 

  52. Sun XW, Kuhn L, Ellerbrock TV, et al.: Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997, 337:1343–1349.

    Article  PubMed  CAS  Google Scholar 

  53. Ho GYF, Burk RD, Fleming I, Klien RS: Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 1994, 56:788–792.

    Article  PubMed  CAS  Google Scholar 

  54. Seck AC, Faye MA, Critchlow CW, et al.: Cervical intraepithelial neoplasia and human papillomavirus infection among Senegalese women seropositive for HIV-1 or HIV-2 or seronegative for HIV. Int J STD AIDS 1994, 5:189–193.

    PubMed  CAS  Google Scholar 

  55. Ellerbock TV, Chiasson MA, Bush TJ, et al.: Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000, 283:1031–1037.

    Article  Google Scholar 

  56. Fink MJ, Fruchter FG, Maiman M, et al.: The adequacy of cytology and colposcopy in diagnosing cervical neoplasia in HIV-seropositive women. Gynecol Oncol 1994, 55:133–137.

    Article  PubMed  CAS  Google Scholar 

  57. Fruchter RG, Maiman M, Sillman FH, et al.: Characteristics of cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus. Am J Obstet Gynecol 1994, 171:531–537.

    PubMed  CAS  Google Scholar 

  58. Petry KU, Bohmer G, Iftner T, et al.: Human papillomavirus testing in primary screening for cervical cancer of human immunodeficiency virus-infected women, 1990–1998. Gynecol Oncol 1999, 75:427–431.

    Article  PubMed  CAS  Google Scholar 

  59. Goldie SJ, Freedberg KA, Weinstein MC, Kuntz KM: HPV testing to augment cervical cytology screening in HIV+ women [abstract]. In Proceedings of the 18th International Papillomavirus Conference. Barcelona, Spain: July 24–28, 2000.

  60. Heard I, Schmitz V, Costagliola D, et al.: Early regression of cervical lesions in HIV-seropositive women receiving highly active anti-retroviral therapy. AIDS 1998, 12:1459–1464.

    Article  PubMed  CAS  Google Scholar 

  61. Womack SD, Chirenje M, Gaffkin L, et al.: HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 2000, 85:206–210.

    PubMed  CAS  Google Scholar 

  62. Schiffman M, Herrero R, Hildesheim A, et al.: HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000, 283:87–93.

    Article  PubMed  CAS  Google Scholar 

  63. Jenkins D, Sherlaw-Johnson C, Gallivan S: Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996, 65:768–773.

    Article  PubMed  CAS  Google Scholar 

  64. Van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, et al.: Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-) effectiveness. Br J Cancer 1997, 76:651–657.

    PubMed  Google Scholar 

  65. Kaufman RH, Adam E, Icenogle J, Reeves WC: Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity and costeffectiveness. Am J Obstet Gynecol 1997, 177:930–936.

    Article  PubMed  CAS  Google Scholar 

  66. Goldie SJ, Denny L, Kuhn L, et al.: Cost-effectiveness of cervical cancer screening in low resource setting [abstract]. In Proceedings of the 18th International Papillomavirus Conference. Barcelona, Spain: July 24–28, 2000.

Download references

Author information

Authors and Affiliations

  1. HPV Research Group, University of Washington, Suite 300, 1914 N. 34th Street, 98103, Seattle, WA, USA

    Shalini L. Kulasingam PhD & Laura A. Koutsky PhD

Authors
  1. Shalini L. Kulasingam PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura A. Koutsky PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kulasingam, S.L., Koutsky, L.A. Will new human papillomavirus diagnostics improve cervical cancer control efforts?. Curr Infect Dis Rep 3, 169–180 (2001). https://doi.org/10.1007/s11908-996-0054-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-996-0054-0

Keywords

Search

Navigation